TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00884897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin given as 20 IU BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as 20 IU BID
Study: NCT01915797

Intervention type: OTHER
Intervention: blood and tumor samples
Description: all tumor pathology associated with anomaly of development
Study: NCT04237285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation aromatherapy
Description: Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Description: Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Description: Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
Study: NCT00785954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
Study: NCT02102412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
Study: NCT00820261

Intervention type: OTHER
Intervention: oral rehydration therapy for diarrhea cases
Description: Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
Study: NCT01508338

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak ATP and HMB
Description: One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ATP
Description: One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
Study: NCT04325633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Naproxen
Description: Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2: Standard of care
Description: Standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2: Standard of care
Description: Standard of care
Study: NCT03330613

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PAEDS
Description: pediatric emergency delirium scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PAEDS
Description: pediatric emergency delirium scale

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TIVA
Description: Total intravenous anesthesia with propofol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: Total intravenous anesthesia with propofol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inhalational anesthesia
Description: Inhalational (volatile) anesthesia with sevoflurane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthesia
Description: Inhalational (volatile) anesthesia with sevoflurane
Study: NCT01602510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02920840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta-burst stimulation
Description: see associated arm/group description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-peak-triggered-TMS
Description: see associated arm/group description

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop replay TMS
Description: see associated arm/group description
Study: NCT00980590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Scope
Description: Tracheal intubation by Airway Scope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Tracheal intubation by Macintosh Laryngoscope
Study: NCT01844713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workbook
Description: Subjects will read a workbook about sun protection
Study: NCT00547534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 on days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 90 mg/m\^2 days 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 day 1
Study: NCT01151215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet, oral, bd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet, oral, bd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Tablet, oral, od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Tablet, oral, od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: Tablet, oral, od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral
Study: NCT03463551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL-101
Description: ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Placebo
Study: NCT03850275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
Study: NCT03739801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT00940576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mare´s milk
Description: oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mare´s milk
Description: oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo drink
Description: oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
Study: NCT03745248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Standard of care
Study: NCT01114295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy
Description: Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Enterography
Description: CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
Study: NCT04086381

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: 5 grams of creatine monohydrate, four times daily, for 9 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo cellulose
Description: oral ingestion of placebo containing 20 gram cellulose daily
Study: NCT03724019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
Study: NCT00758329

Intervention type: DEVICE
Intervention: ReCap Total Hip Resurfacing
Description: ReCap Total Hip Resurfacing
Study: NCT03090503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Initial dose: 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose: 2 mg.
Study: NCT02588729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnant+ app for smartphone
Description: The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
Study: NCT04798326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW032
Description: Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
Study: NCT03351153

Intervention type: RADIATION
Group type: OTHER
Intervention: X-ray
Description: In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week

Intervention type: RADIATION
Group type: OTHER
Intervention: CT
Description: In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week

Intervention type: OTHER
Group type: OTHER
Intervention: specimen
Description: In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
Study: NCT01515566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9% preservative free SQ 15 minutes before walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Tests
Description: 6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Tests
Description: 6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
Study: NCT00481013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: Drug: Valproic Acid and Levocarnitine; capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
Study: NCT05111938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friends, Family, and Food App (F3A-App)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friends, Family, and Food App (F3A-App)
Study: NCT03363308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training for health care workers supplmented by QI teams
Description: Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
Study: NCT00670657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
Study: NCT00634686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/EPA
Description: 1.2 gram capsule daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D
Description: 1000 mg of calcium with 1000 IU vitamin D daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium with vitamin D
Description: 1000 mg of calcium with 1000 IU vitamin D daily for 6 months
Study: NCT02126124

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active dTMS Treatment
Description: Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
Study: NCT01841034

Intervention type: DRUG
Intervention: Conceptio EA
Description: The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
Study: NCT00802958

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of a day

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of a day

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of a day

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Test Product
Description: Small amount applied and evaluated over the course of a day

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Test Product
Description: Small amount applied and evaluated over the course of a day

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Test Product
Description: Small amount applied and evaluated over the course of a day
Study: NCT01908582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administered orally
Study: NCT03409484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape Juice
Description: Concord Grape Juice

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavoniod low essence beverage
Description: Low flavoniod low essence beverage

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid beverage
Description: Low flavonoid beverage
Study: NCT03911947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrolung
Description: Device for vibroacoustic respiratory therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrolung
Description: Device for vibroacoustic respiratory therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrolung
Description: Device for vibroacoustic respiratory therapy
Study: NCT03850275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.